FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Visual Impairment in Senior Adults Apellis Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved SYFOVRE™ (pegcetacoplan injection) 15mg/0.1mL, the first and only treatment for geographic atrophy (GA) secondary to age-related [Read More]
Author: Dan Roberts
Important Information About SYFOVRE
Do not receive SYFOVRE if you: have an infection in or around your eye have active swelling in or around your eye that may include pain and redness SYFOVRE can cause serious side effects: Eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment) Call your healthcare provider right away if you have [Read More]
Does VUITY™ Treat AMD?
A new drug called VUITY™ (pilocarpine hydrochloride ophthalmic solution) has recently gained attention as an eye drop that can improve near (close up) vision in individuals over 40. It does not, however, change the condition of the retina. The drug, made by Allergan, works as advertised, but it should not be expected to treat age-related [Read More]
APL-2 (pegcetacoplan) May Soon Become the First Treatment for Geographic Atrophy
Apellis Pharmaceuticals has announced long term results from their Phase 3 DERBY and OAKS clinical studies, testing the efficacy and safety of APL-2 (now called intravitreal pegcetacoplan), as a treatment for geographic atrophy (GA). GA is also known as advanced dry age-related macular degeneration. In an analysis conducted at month 18 of the clinical studies, treatment [Read More]
Long-awaited Faricimab for wet AMD and DME approved
The FDA has approved Genentech’s Vabysmo (first announced here as faricimab), the only injectable eye medicine approved simultaneously in the U.S. for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Vabysmo will be administered using flexible dosing regimens based on patient need. The medication targets and inhibits two disease pathways by neutralizing angiopoietin-2 [Read More]